Lixte: Rises on agreement with medical center for lung cancer drug trial

NOMAD Power Solutions

19/01/2021 15:32

** Drug developer's shares  LIXT.O  jump 16% to $3.64 
    ** LIXT enters agreement with cancer research and treatment
center City of Hope for an early-stage trial of LIXT's
experimental drug, LB-100  urn:newsml:reuters.com:*:nGNX15n5Z0
    ** Trial to assess combination of LB-100 with standard drug
regimen for untreated, extensive stage-disease small cell lung
cancer - LIXT 
    ** Says dose of LB-100 will be escalated with fixed doses of
3-drug regimen to reach a recommended Phase 2 dose
    ** 12 patients to be evaluable at the recommended Phase 2
dose to confirm its safety and to look for objective evidence of
potential therapeutic activity, says co
    ** Small cell lung cancer comprises ~15% of all lung cancers
worldwide with about 30,000 new cases annually in the U.S.,
according to co

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))